​

SpringWorks Therapeutics (SWTX) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

SpringWorks Therapeutics Revenue Highlights

Latest Revenue (Y)

$191.59M

Latest Revenue (Q)

$59.73M

SpringWorks Therapeutics Revenue by Period

SpringWorks Therapeutics Revenue by Year

DateRevenueChange
2024-12-31$191.59M3417.33%
2023-12-31$5.45M-11.39%
2022-12-31$6.15M100.00%
2021-12-31--100.00%
2020-12-31$35.00M100.00%
2019-12-31-100.00%
2018-12-31-100.00%
2017-12-31--

SpringWorks Therapeutics generated $191.59M in revenue during NA 2024, up 3417.33% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

SpringWorks Therapeutics Revenue by Quarter

DateRevenueChange
2024-06-30$59.73M184.36%
2024-03-31$21.01M285.64%
2023-12-31$5.45M-2.49%
2023-09-30$5.59M-4.15%
2023-06-30$5.83M4.88%
2023-03-31$5.56M-4.17%
2022-12-31$5.80M592.00%
2022-09-30$838.00K140.80%
2022-06-30$348.00K6860.00%
2022-03-31$5.00K100.00%
2021-12-31--100.00%
2021-09-30$121.00K-28.82%
2021-06-30$170.00K-26.09%
2021-03-31$230.00K-99.34%
2020-12-31$35.00M100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31--

SpringWorks Therapeutics generated $59.73M in revenue during Q2 2024, up 184.36% compared to the previous quarter, and up 1074.91% compared to the same period a year ago.

SpringWorks Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
APLSApellis Pharmaceuticals$709.95M$176.57M
BPMCBlueprint Medicines$508.82M$128.18M
ARVNArvinas$263.40M$102.40M
SWTXSpringWorks Therapeutics$191.59M$59.73M
DAWNDay One Biopharmaceuticals$131.16M$20.07M
AMLXAmylyx Pharmaceuticals$87.37M$416.00K
GLUEMonte Rosa Therapeutics$75.62M$4.70M
KYMRKymera Therapeutics$47.07M$3.74M
STOKStoke Therapeutics$36.55M$4.89M
RNAAvidity Biosciences$10.90M$2.04M
RLAYRelay Therapeutics$10.01M-
BDTXBlack Diamond Therapeutics--
RVMDRevolution Medicines--
SANASana Bio--
TERNTerns Pharmaceuticals--
PLRXPliant Therapeutics--
PASGPassage Bio--

SWTX Revenue FAQ

What is SpringWorks Therapeutics’s yearly revenue?

SpringWorks Therapeutics's yearly revenue for 2024 was $191.59M, representing an increase of 3417.33% compared to 2023. The company's yearly revenue for 2023 was $5.45M, representing a decrease of -11.39% compared to 2022. SWTX's yearly revenue for 2022 was $6.15M, representing an increase of 100.00% compared to 2021.

What is SpringWorks Therapeutics’s quarterly revenue?

SpringWorks Therapeutics's quarterly revenue for Q2 2024 was $59.73M, a 184.36% increase from the previous quarter (Q1 2024), and a 924.93% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $21.01M, a 285.64% increase from the previous quarter (Q4 2023), and a 278.01% increase year-over-year (Q1 2023). SWTX's quarterly revenue for Q4 2023 was $5.45M, a -2.49% decrease from the previous quarter (Q3 2023), and a -6.07% decrease year-over-year (Q4 2022).

What is SpringWorks Therapeutics’s revenue growth rate?

SpringWorks Therapeutics's revenue growth rate for the last 3 years (2022-2024) was 3016.79%, and for the last 5 years (2020-2024) was 447.40%.